87394-48-7

Basic information

• Product Name: 1-(3-Nitorpyridin-2-yl)piperazine
• Synonyms: 1-(3-Nitorpyridin-2-yl)piperazine2-yl)piperazine;1-(3-Nitorpyridin-2-yl)piperazine;1-(3-Nitropyridin-2-yl)piperazine ,97%;1-(3-nitropyridin-2-yl)piperazine dihydrochloride;piperazine, 1-(3-nitro-2-pyridinyl)-;1-(3-Nitro-2-pyridyl)piperazine, 97%
• CAS NO: 87394-48-7
• Molecular Formula: C₉H₁₂N₄O₂
• Molecular Weight: 208.22
• EINECS: 201-215-5
• Product Categories: pharmacetical;Pyridines
• Mol File: 87394-48-7.mol

Chemical Properties

• Melting Point: 84-86
• Boiling Point: 387.8 °C at 760 mmHg
• Flash Point: 188.4 °C
• Appearance: /
• Density: 1.278 g/cm³
• Vapor Pressure: 3.2E-06mmHg at 25°C
• Refractive Index: 1.583
• Storage Temp.: 2-8°C
• PKA: 8.25±0.10(Predicted)
• CAS DataBase Reference: 1-(3-Nitorpyridin-2-yl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-Nitorpyridin-2-yl)piperazine(87394-48-7)
• EPA Substance Registry System: 1-(3-Nitorpyridin-2-yl)piperazine(87394-48-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 87394-48-7(Hazardous Substances Data)

Usage

Chemical Properties

Yellow solid

InChI:InChI=1/C9H12N4O2/c14-13(15)8-2-1-3-11-9(8)12-6-4-10-5-7-12/h1-3,10H,4-7H2

Upstream product

• 5470-18-8 2-Chloro-3-nitropyridine 
• 142-64-3 piperazine dihydrochloride 
• 110-85-0 piperazine 

Downstream Products

• 1620488-60-9 1-(4-fluorophenyl)-2-imidazol-1-yl-ethyl 4-(3-nitro-2-pyridyl)piperazine-1-carboxylate 
• 111669-26-2 4-(3-ethylaminopyridin-2-yl)piperazine-1-carboxylic acid tert-butyl ester 
• 111669-24-0 4-[3-(Ethylamino)-2-pyridinyl]-piperazine 
• 403502-22-7 [2-chloro-5-(3-nitro-phenyl)-1H-pyrrol-3-yl]-[4-(3-isopropylamino-pyridin-2-yl)-piperazin-1-yl]-methanone 
• 403502-21-6 [2-chloro-5-(4-nitro-phenyl)-1H-pyrrol-3-yl]-[4-(3-isopropylamino-pyridin-2-yl)-piperazin-1-yl]-methanone 
• 403502-23-8 [2-chloro-5-(2-nitro-phenyl)-1H-pyrrol-3-yl]-[4-(3-isopropylamino-pyridin-2-yl)-piperazin-1-yl]-methanone 
• 403502-17-0 [4-[3-(isopropylamino)-2-pyridyl]piperazino]-[5-(4-nitrophenyl)-1H-2-pyrrolyl]methanone 
• 403502-19-2 [4-(3-isopropylamino-pyridin-2-yl)-piperazin-1-yl]-[5-(3-nitro-phenyl)-1H-pyrrol-2-yl]-methanone 
• 403502-46-5 [5-(4-amino-phenyl)-1H-pyrrol-3-yl]-[4-(3-isopropylamino-pyridin-2-yl)-piperazin-1-yl]-methanone 
• 403502-41-0 [5-(2-amino-phenyl)-1H-pyrrol-2-yl]-[4-(3-isopropylamino-pyridin-2-yl)-piperazin-1-yl]-methanone 
• 403502-20-5 [4-(3-isopropylamino-pyridin-2-yl)-piperazin-1-yl]-[5-(2-nitro-phenyl)-1H-pyrrol-2-yl]-methanone 
• 403502-48-7 [5-(2-amino-phenyl)-1H-pyrrol-3-yl]-[4-(3-isopropylamino-pyridin-2-yl)-piperazin-1-yl]-methanone 

Relevant articles and documents

PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS

The present invention relates to pyrimido[5,4-d]pyrimidine derivatives of formula (I), including pharmaceutically acceptable salts and solvates thereof. Compounds of the invention are inhibitors of ENT family transporter, especially of ENT1, and are useful as therapeutic compounds for the treatment of cancers. The invention also relates to the combined use of the pyrimido[5,4-d]pyrimidine derivatives with an adenosine receptor antagonist, for the treatment of cancers.

Synthesis, biological evaluation and structure-activity correlation study of a series of imidazol-based compounds as Candida albicans inhibitors

A new series of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives was synthesized. The antifungal activity was evaluated in vitro against different fungal species. The biological results show that the most active compounds possess an antifungal activity comparable or higher than Fluconazole against Candida albicans, non-albicans Candida species, Cryptococcus neoformans and dermathophytes. Because of their racemic nature, the most active compounds 5f and 6c were tested as pure enantiomers. For 6c the (R)-enantiomer resulted more active than the (S)-one, otherwise for 5f the (S)-enantiomer resulted the most active. To rationalize the experimental data, a ligand-based computational study was carried out; the results of the modelling study show that (S)-5f and (R)-6c perfectly align to the ligand-based model, showing the same relative configuration. Preliminary studies on the human lung adenocarcinoma epithelial cells (A549) have shown that 6c, 5e and 5f possess a low cytotoxicity.

Strategy for 14C-labeling of a series of bis(heteroaryl) piperazines

Four bis(heteroaryl)piperazines labeled with carbon-14 in the 2-position of imidazole moiety were prepared as part of a 4-step (or 5-step) sequence from 5-hydroxymethyl-2-mercapto-1-benzylimida-zole-[2-14C] as a key synthetic intermediate which

PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS

Compounds of Formula I or pharmaceutically acceptable salts or solvates thereof, wherein A, B, D, Ar1, Ar2, R2, R3, R4, a, m and n are defined in the specification, methods for the use thereof, processes for making and pharmaceutical compositions containing the same.

Discovery and Initial SAR of Arylsulfonylpiperazine Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)

High-throughput screening of a small-molecule compound library resulted in the identification of a series of arylsulfonylpiperazines that are potent and selective inhibitors of human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1). Optimization of the initial lead resulted in the discovery of compound (R)-45 (11β-HSD1 IC50 = 3 nM).

Substituted piperazines as metabotropic glutamate receptor antagonists

The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar1, Ar2, Hy, L, R1, m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses thereof, processes for making the compounds, as well as methods for the medical treatment of mGluR5-mediated disorders.

THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN

Compounds of formulae (I) and (II) where X is S or O and Ar2, R1, R2, R3, R8, n, m, and t are disclosed herein, or a pharmaceutically acceptable salt thereof (a "3-substituted Pyridyl Compound"), comp

Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2- yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist

High throughput screening using the recombinant human TRPV1 receptor was used to identify a series of pyridinylpiperazine ureas (3) as TRPV1 vanilloid receptor ligands. Exploration of the structure-activity relationships by parallel synthesis identified t

Acetamides and benzamides that are useful in treating sexual dysfunction

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

4-(2-Pyridyl)piperazine-1-carboxamides: Potent vanilloid receptor 1 antagonists

A series of 4-(2-pyridyl)piperazine-1-carboxamide analogues based on the lead compound 1 was synthesized and evaluated for VR1 antagonist activity in capsaicin-induced (CAP) and pH (5.5)-induced (pH) FLIPR assays in a rat VR1-expressing HEK293 cell line. Potent VR1 antagonists were identified through SAR studies. From these studies, 18 was found to be very potent in the in vitro assay [IC50=4.8 nM (pH) and 35 nM (CAP)] and orally available in rat (F%=15.1).